S 511

RU-486 Suspension and Review Act of 2005

Congress: 109 (2005–2007, Ended)
Chamber: Senate
Policy Area: Health
Introduced: Mar 3, 2005
Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure
Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2020-2021) (Mar 3, 2005)
Official Text: https://www.congress.gov/bill/109th-congress/senate-bill/511

Sponsor

Name: Sen. DeMint, Jim [R-SC]
Party: Republican • **State:** SC • **Chamber:** Senate

Cosponsors (12 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Allen, George [R-VA]	R · VA		Mar 3, 2005
Sen. Brownback, Sam [R-KS]	R · KS		Mar 3, 2005
Sen. Coburn, Tom [R-OK]	R · OK		Mar 3, 2005
Sen. Ensign, John [R-NV]	R · NV		Mar 3, 2005
Sen. Enzi, Michael B. [R-WY]	R · WY		Mar 3, 2005
Sen. Inhofe, James M. [R-OK]	R · OK		Mar 3, 2005
Sen. Santorum, Rick [R-PA]	R · PA		Mar 3, 2005
Sen. Vitter, David [R-LA]	R · LA		Mar 3, 2005
Sen. Bunning, Jim [R-KY]	R · KY		Jul 11, 2005
Sen. Thune, John [R-SD]	R · SD		Sep 7, 2005
Sen. DeWine, Mike [R-OH]	R · OH		Sep 21, 2005
Sen. Martinez, Mel [R-FL]	R · FL		May 2, 2006

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Mar 3, 2005

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
109 HR 1079	Related bill	**Mar 14, 2005:** Referred to the Subcommittee on Health.

Summary (as of Mar 3, 2005)

RU-486 Suspension and Review Act of 2005 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been withdrawn.

Deems the drug misoprostol as misbranded under the Federal Food, Drug, and Cosmetic Act (FFDCA) if it bears labeling providing that the drug may be used for the medical termination of intrauterine pregnancy.

Directs the Comptroller General to review and report on the process by which the Food and Drug Administration (FDA) approved mifepristone. Provides for the reinstatement of the approved application for such drug if the report determines the approval to have been in accordance with FFDCA.

Actions Timeline

- **Mar 3, 2005:** Introduced in Senate
- **Mar 3, 2005:** Sponsor introductory remarks on measure. (CR S2020)
- **Mar 3, 2005:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2020-2021)

LegiList

CONGRESS, MADE CLEAR.

Search Every Federal Bill, Law, and Vote

LegiList is the fastest way to research Congress. Track any bill from introduction to enactment, see how every legislator voted, follow committee activity, and read the full text of every bill — all in one place, always up to date.

legilist.com

Free Course: Learn How Congress Actually Works

LegiList Learn is a free, self-paced course that walks through the entire legislative process — from drafting a bill to a presidential signature. Seven modules, plain language, no politics. Earn a certificate when you finish.

legilist.com/learn

Developer API: Build Apps on Legislative Data

The LegiList API gives developers direct access to bills, votes, legislators, committees, and more. Start free with 1,000 requests per day — no credit card required. Upgrade to Pro when you need to scale.

legilist.com/api

Public data belongs to the public. — legilist.com